TABLE 4.
Predictors of Change in QUIP‐RS Scores; Results from Linear Mixed‐Effects Model; Model Adjusting for LED‐DA
| Variable | β (standard error) | 95% CI | P‐value |
|---|---|---|---|
| Intercept | 9.021 (4.815) | (−0.633, 18.675) | 0.066 |
| Age | −0.075 (0.07) | (−0.216, 0.066) | 0.29 |
| Female sex (Male reference) | −1.899 (1.353) | (−4.62, 0.821) | 0.167 |
| Disease duration | −0.136 (0.106) | (−0.349, 0.078) | 0.207 |
| LED‐DA total | 0.001 (0.004) | (−0.006, 0.009) | 0.75 |
| QUIP‐RS score (Baseline) | 0.508 (0.058) | (0.39, 0.625) | <0.001 |
| Timepoint (Baseline reference) | 0.876 | ||
| 3 months | −0.094 (1.506) | (−3.071, 2.883) | 0.95 |
| 6 months | −0.333 (1.489) | (−3.277, 2.61) | 0.823 |
| 1 year | 0.836 (1.491) | (−2.112, 3.783) | 0.576 |
| DBS versus control | 1.149 (1.638) | (−2.085, 4.383) | 0.484 |
| Treatment (DBS) * Time | 0.456 | ||
| DBS group: 3 months | −1.895 (2.179) | (−6.202, 2.412) | 0.386 |
| DBS group: 6 months | −3.156 (2.184) | (−7.473, 1.161) | 0.151 |
| DBS group: 1 year | −2.848 (2.154) | (−7.105, 1.409) | 0.188 |
Abbreviations: DBS, deep brain stimulation; LED‐DA, levodopa equivalent dose from dopamine agonists; QUIP‐RS, questionnaire for impulse control disorders in Parkinson's disease rating scale.